share_log

Guggenheim Initiates Coverage On ADC Therapeutics With Buy Rating, Announces Price Target of $11

Moomoo 24/7 ·  Mar 28 06:45

Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Buy rating and announces Price Target of $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment